Istituto Superiore di Sanitá, National Center for Drug Research and Evaluation, Rome, Italy.
Ankara University, Faculty of Medicine, Department of Pharmacology, Molecular biology and Technology development unit, Sıhhiye, Ankara, Turkey.
Sci Rep. 2020 Jun 4;10(1):9111. doi: 10.1038/s41598-020-65996-w.
Vasopressin receptor 2 (V2R) mutations causing the nephrogenic syndrome of inappropriate antidiuresis (NSIAD) can generate two constitutively active receptor phenotypes. One type results from residue substitutions in several V2R domains and is sensitive to vaptan inverse agonists. The other is only caused by Arg 137 replacements and is vaptan resistant. We compared constitutive and agonist-driven interactions of the vaptan-sensitive F229V and vaptan-resistant R137C/L V2R mutations with β-arrestin 1, β-arrestin 2, and Gαs, using null fibroblasts reconstituted with individual versions of the ablated transduction protein genes. F229V displayed very high level of constitutive activation for Gs but not for β-arrestins, and enhanced or normal responsiveness to agonists and inverse agonists. In contrast, R137C/L mutants exhibited maximal levels of constitutive activation for βarrestin 2 and Gs, minimal levels for β-arrestin 1, but a sharp decline of ligands sensitivity at all transducer interactions. The enhanced constitutive activity and reduced ligand sensitivity of R137 mutants on cAMP signaling persisted in cells lacking β-arrestins, indicating that these are intrinsic molecular properties of the mutations, not the consequence of altered receptor trafficking. The results suggest that the two groups of NSIAD mutations represent two distinct molecular mechanisms of constitutive activation in GPCRs.
血管加压素受体 2 (V2R) 突变导致的抗利尿激素不适当分泌综合征 (NSIAD) 可产生两种组成型激活的受体表型。一种类型是由于 V2R 几个结构域中的残基取代引起的,对 vaptan 反向激动剂敏感。另一种仅由 Arg137 取代引起,对 vaptan 具有抗性。我们比较了 vaptan 敏感的 F229V 和 vaptan 抗性的 R137C/L V2R 突变与β-arrestin1、β-arrestin2 和 Gαs 的组成型和激动剂驱动相互作用,使用单个突变的消融转导蛋白基因重建的无功能纤维母细胞进行比较。F229V 显示出非常高水平的 Gs 组成型激活,但对β-arrestin 没有作用,并且对激动剂和反向激动剂的反应增强或正常。相比之下,R137C/L 突变体表现出β-arrestin2 和 Gs 的最大组成型激活水平,β-arrestin1 的最低水平,但在所有转导相互作用中配体敏感性急剧下降。在缺乏β-arrestin 的细胞中,R137 突变体在 cAMP 信号传导中的增强组成型活性和降低配体敏感性仍然存在,这表明这些是突变的固有分子特性,而不是受体运输改变的结果。结果表明,两组 NSIAD 突变代表 GPCR 组成型激活的两种不同分子机制。